ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "71ae8dab-1a8e-4a2c-b865-7128fc120f7c"}, "_deposit": {"id": "13017", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "13017"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00013017", "sets": []}, "author_link": ["40908", "40909", "40910", "40911", "40912", "40913", "40914", "40915"], "item_1615768549627": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1-2", "bibliographicPageEnd": "31", "bibliographicPageStart": "25", "bibliographicVolumeNumber": "73", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science", "bibliographic_titleLang": "en"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Lansoprazole (LPZ), amoxicillin (AMPC) and clarithromycin (CAM) are commonly used drugs (LAC regimen) for Helicobacter pylori (H. pylori) eradication, but the eradication rate with this regimen was reported to be 70% to 90%. A few studies have reported that a successful eradication was associated with the CYP2C19 genotype, which influences the metabolism of proton pump inhibitors (PPI) including LPZ. This study examined the changes in the H. pylori eradication rates between the periods before and after the commencement of a routine genetic test for CYP2C19 at the Daiko Medical Center in Nagoya, Japan, in November, 2005. Subjects were patients who visited the Center during the period from June, 2004 to August, 2010. The patients were classified into three groups according to their CYP2C19 genotype: rapid metabolizers (RM) with a *1*1 genotype, intermediate metabolizers (IM) with a *1*2 or *1*3 genotype, and poor metabolizers (PM) with a *2*2, *2*3, or *3*3 genotype. Non-rapid metabolizers (IM and PM) were basically treated with a LAC regimen, while RMs were treated with a RAM regimen (rabeprazole, AMPC, and metronidazole). The eradication rate was 80.0% (n=90) for the period without the genetic testing and 88.7% (n=124) for the period with the genetic testing (χ2=3.11, p=0.078). The age-sex adjusted odds ratio of eradication success was 2.29 (95% confidence interval, 0.99–5.28, p=0.051) for the latter period relative to the former period among those less than 70 years of age. Those results suggested that the routine genetic test which allows a choice of the RAM regimen for RM improved the eradication rate.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_9_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "URI", "subitem_identifier_uri": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7312/7312.html"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/14912"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.73.1-2.25", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University School of Medicine", "subitem_publisher_language": "en"}]}, "item_9_relation_43": {"attribute_name": "関連情報", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7312/7312.html", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "PISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "TAMURA, TAKASHI", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "40908", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KURATA, MIO", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "40909", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "INOUE, SHIGERU", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "40910", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KONDO, TAKAAKI", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "40911", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "GOTO, YASUYUKI", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "40912", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KAMIYA, YOSHIKAZU", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "40913", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KAWAI, SAYO", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "40914", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "HAMAJIMA, NOBUYUKI", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "40915", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-20"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "v73n12p25_31.pdf", "filesize": [{"value": "94.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 94300.0, "url": {"label": "v73n12p25_31.pdf", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/13017/files/v73n12p25_31.pdf"}, "version_id": "f4ec85e3-4741-4dd1-b90f-e49d7ae00f2a"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Helicobacter pylori", "subitem_subject_scheme": "Other"}, {"subitem_subject": "CYP2C19 genotype", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Proton pump inhibitor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Eradication rate", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "IMPROVEMENTS IN HELICOBACTER PYLORI ERADICATION RATES THROUGH CLINICAL CYP2C19 GENOTYPING", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "IMPROVEMENTS IN HELICOBACTER PYLORI ERADICATION RATES THROUGH CLINICAL CYP2C19 GENOTYPING", "subitem_title_language": "en"}]}, "item_type_id": "9", "owner": "1", "path": ["1326"], "permalink_uri": "https://doi.org/10.18999/nagjms.73.1-2.25", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2011-06-01"}, "publish_date": "2011-06-01", "publish_status": "0", "recid": "13017", "relation": {}, "relation_version_is_last": true, "title": ["IMPROVEMENTS IN HELICOBACTER PYLORI ERADICATION RATES THROUGH CLINICAL CYP2C19 GENOTYPING"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 73(1-2)

IMPROVEMENTS IN HELICOBACTER PYLORI ERADICATION RATES THROUGH CLINICAL CYP2C19 GENOTYPING

https://doi.org/10.18999/nagjms.73.1-2.25
https://doi.org/10.18999/nagjms.73.1-2.25
4a8e1f59-95f9-409b-8502-4204ddd9cffc
名前 / ファイル ライセンス アクション
v73n12p25_31.pdf v73n12p25_31.pdf (94.3 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2011-06-01
タイトル
タイトル IMPROVEMENTS IN HELICOBACTER PYLORI ERADICATION RATES THROUGH CLINICAL CYP2C19 GENOTYPING
言語 en
著者 TAMURA, TAKASHI

× TAMURA, TAKASHI

WEKO 40908

en TAMURA, TAKASHI

Search repository
KURATA, MIO

× KURATA, MIO

WEKO 40909

en KURATA, MIO

Search repository
INOUE, SHIGERU

× INOUE, SHIGERU

WEKO 40910

en INOUE, SHIGERU

Search repository
KONDO, TAKAAKI

× KONDO, TAKAAKI

WEKO 40911

en KONDO, TAKAAKI

Search repository
GOTO, YASUYUKI

× GOTO, YASUYUKI

WEKO 40912

en GOTO, YASUYUKI

Search repository
KAMIYA, YOSHIKAZU

× KAMIYA, YOSHIKAZU

WEKO 40913

en KAMIYA, YOSHIKAZU

Search repository
KAWAI, SAYO

× KAWAI, SAYO

WEKO 40914

en KAWAI, SAYO

Search repository
HAMAJIMA, NOBUYUKI

× HAMAJIMA, NOBUYUKI

WEKO 40915

en HAMAJIMA, NOBUYUKI

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
キーワード
主題Scheme Other
主題 Helicobacter pylori
キーワード
主題Scheme Other
主題 CYP2C19 genotype
キーワード
主題Scheme Other
主題 Proton pump inhibitor
キーワード
主題Scheme Other
主題 Eradication rate
抄録
内容記述 Lansoprazole (LPZ), amoxicillin (AMPC) and clarithromycin (CAM) are commonly used drugs (LAC regimen) for Helicobacter pylori (H. pylori) eradication, but the eradication rate with this regimen was reported to be 70% to 90%. A few studies have reported that a successful eradication was associated with the CYP2C19 genotype, which influences the metabolism of proton pump inhibitors (PPI) including LPZ. This study examined the changes in the H. pylori eradication rates between the periods before and after the commencement of a routine genetic test for CYP2C19 at the Daiko Medical Center in Nagoya, Japan, in November, 2005. Subjects were patients who visited the Center during the period from June, 2004 to August, 2010. The patients were classified into three groups according to their CYP2C19 genotype: rapid metabolizers (RM) with a *1*1 genotype, intermediate metabolizers (IM) with a *1*2 or *1*3 genotype, and poor metabolizers (PM) with a *2*2, *2*3, or *3*3 genotype. Non-rapid metabolizers (IM and PM) were basically treated with a LAC regimen, while RMs were treated with a RAM regimen (rabeprazole, AMPC, and metronidazole). The eradication rate was 80.0% (n=90) for the period without the genetic testing and 88.7% (n=124) for the period with the genetic testing (χ2=3.11, p=0.078). The age-sex adjusted odds ratio of eradication success was 2.29 (95% confidence interval, 0.99–5.28, p=0.051) for the latter period relative to the former period among those less than 70 years of age. Those results suggested that the routine genetic test which allows a choice of the RAM regimen for RM improved the eradication rate.
言語 en
内容記述タイプ Abstract
出版者
言語 en
出版者 Nagoya University School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
ID登録
ID登録 10.18999/nagjms.73.1-2.25
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7312/7312.html
ISSN(print)
収録物識別子タイプ PISSN
収録物識別子 0027-7622
書誌情報 en : Nagoya Journal of Medical Science

巻 73, 号 1-2, p. 25-31, 発行日 2011-02
著者版フラグ
値 publisher
URI
識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7312/7312.html
識別子タイプ URI
URI
識別子 http://hdl.handle.net/2237/14912
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 09:52:42.624024
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3